Dar Al Dawa Development & Investment Co

dadgroup.com

Dar Al Dawa is a MENA-wide leader in Pharmaceutical and consumer health products. With a history of more than 40 years. As a fully integrated Pharmaceutical company, we have a long established customer-centered approach to developing, producing, marketing and commercializing high-quality affordable medicines and wellness consumer products in emerging markets, with more than 900 people serving patients in more than 40 countries throughout Middle East, North Africa and Europe.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

ZYNEX SUBMITS FDA APPLICATION FOR ITS NEXT GENERATION FLUID AND BLOOD VOLUME MONITOR

Zynex | January 04, 2022

news image

Zynex, Inc. an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration for the CM-1600, its next generation fluid monitoring system. "I am thrilled to announce that we have submitted a 510(k) premarket notification to the FDA for our CM...

Read More

Business Insights

LIGAND PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Ligand Pharmaceuticals | August 02, 2022

news image

Ligand Pharmaceuticals Incorporated announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 90,073 shares of its common stock, 5,000 restricted stock units and 4,000 performance stock units the target level to six non-executive employees. The options were granted on August 1, 2022, and the grant date for the RSUs and the PSUs will be the date on which Ligand files a Form S-8 Registration Statem...

Read More

PARALLEL'S SURTERRA WELLNESS STORES TO INTRODUCE NEW PRODUCTS INCLUDING EDIBLES IN FLORIDA

Prnewswire | August 31, 2020

news image

Parallel, formerly known nationally as Surterra Holdings, a company pioneering well-being through its proprietary cannabinoid brands, science and technology-led innovation, today announced that it will introduce new edible cannabis products to its customers in its 39 Florida Surterra Wellness stores. This expansion of Surterra Wellness' product offering follows the Florida Department of Health's (FDOH) finalizing recently released emergency rules to allow for the production and sale of e...

Read More

Business Insights

AKORN ANNOUNCES FDA-APPROVED GENERIC CETRORELIX ACETATE FOR INJECTION 0.25 MG

Akorn Pharmaceuticals | August 17, 2022

news image

Akorn Operating Company LLC, a specialty pharmaceutical company, announces that it received FDA approval for a generic version of Cetrorelix Acetate for Injection, 0.25 mg. This is the first approved AP-Rated bioequivalent version of Merck Serono's Cetrotide®.1 "We are pleased to announce the first approved AP-rated generic option for women receiving fertility treatments. As an increasing number of infants are being conceived via the use of ART, ...

Read More
news image

Pharma Tech

ZYNEX SUBMITS FDA APPLICATION FOR ITS NEXT GENERATION FLUID AND BLOOD VOLUME MONITOR

Zynex | January 04, 2022

Zynex, Inc. an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration for the CM-1600, its next generation fluid monitoring system. "I am thrilled to announce that we have submitted a 510(k) premarket notification to the FDA for our CM...

Read More
news image

Business Insights

LIGAND PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Ligand Pharmaceuticals | August 02, 2022

Ligand Pharmaceuticals Incorporated announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 90,073 shares of its common stock, 5,000 restricted stock units and 4,000 performance stock units the target level to six non-executive employees. The options were granted on August 1, 2022, and the grant date for the RSUs and the PSUs will be the date on which Ligand files a Form S-8 Registration Statem...

Read More
news image

PARALLEL'S SURTERRA WELLNESS STORES TO INTRODUCE NEW PRODUCTS INCLUDING EDIBLES IN FLORIDA

Prnewswire | August 31, 2020

Parallel, formerly known nationally as Surterra Holdings, a company pioneering well-being through its proprietary cannabinoid brands, science and technology-led innovation, today announced that it will introduce new edible cannabis products to its customers in its 39 Florida Surterra Wellness stores. This expansion of Surterra Wellness' product offering follows the Florida Department of Health's (FDOH) finalizing recently released emergency rules to allow for the production and sale of e...

Read More
news image

Business Insights

AKORN ANNOUNCES FDA-APPROVED GENERIC CETRORELIX ACETATE FOR INJECTION 0.25 MG

Akorn Pharmaceuticals | August 17, 2022

Akorn Operating Company LLC, a specialty pharmaceutical company, announces that it received FDA approval for a generic version of Cetrorelix Acetate for Injection, 0.25 mg. This is the first approved AP-Rated bioequivalent version of Merck Serono's Cetrotide®.1 "We are pleased to announce the first approved AP-rated generic option for women receiving fertility treatments. As an increasing number of infants are being conceived via the use of ART, ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us